ESTRO 2024 - Abstract Book

S5220

Radiobiology - Microenvironment

ESTRO 2024

Keywords:

NSCLC,

serine,

glycine,

immunosuppression

References:

1. Zhang B, Zheng A, Hydbring P, Ambroise G, Ouchida AT, Goiny M, et al. PHGDH defines a metabolic subtype in lung adenocarcinomas with poor prognosis. Cell reports. 2017;19(11):2289-303.

2. Liao L, Yu H, Ge M, Zhan Q, Huang R, Ji X, et al. Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non ‐ small cell lung cancer patients. Thoracic cancer. 2019;10(5):1203-12. 3. Kampen KR, Fancello L, Girardi T, Rinaldi G, Planque M, Sulima SO, et al. Translatome analysis reveals altered serine and glycine metabolism in T-cell acute lymphoblastic leukemia cells. Nature communications. 2019;10(1):1 16.

4. Heylen E, Verstraete P, Van Aerschot L, Geeraerts SL, Venken T, Timcheva K, et al. Transcription factor NKX2–1 drives serine and glycine synthesis addiction in cancer. British Journal of Cancer. 2023:1-17.

5. Sánchez-Castillo A, Vooijs M, Kampen KR. Linking serine/glycine metabolism to radiotherapy resistance. Cancers. 2021;13(6):1191.

6. Geeraerts SL, Kampen KR, Rinaldi G, Gupta P, Planque M, Louros N, et al. Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine/glycine synthesis–addicted breast tumor growth. Molecular cancer therapeutics. 2021;20(1):50-63.

7. Wang Y, Zhang X, Yang L, Xue J, Hu G. Blockade of CCL2 enhances immunotherapeutic effect of anti-PD1 in lung cancer. Journal of bone oncology. 2018;11:27-32.

8. Nardi V, Naveiras O, Azam M, Daley GQ. ICSBP-mediated immune protection against BCR-ABL–induced leukemia requires the CCL6 and CCL9 chemokines. Blood, The Journal of the American Society of Hematology. 2009;113(16):3813-20.